Gianluigi Condorelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7411280/publications.pdf

Version: 2024-02-01

232 papers	20,453 citations	9234 74 h-index	10708 138 g-index
238 all docs	238 docs citations	238 times ranked	24958 citing authors

#	Article	IF	Citations
1	MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 2007, 13, 613-618.	15.2	1,652
2	ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 2002, 8, 459-465.	15.2	796
3	Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell, 1993, 72, 309-324.	13.5	742
4	The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death and Differentiation, 2009, 16, 1590-1598.	5.0	504
5	Adult c-kitpos Cardiac Stem Cells Are Necessary and Sufficient for Functional Cardiac Regeneration and Repair. Cell, 2013, 154, 827-842.	13.5	469
6	Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12333-12338.	3.3	455
7	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1419-1434.	1.1	385
8	MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart, 2015, 101, 921-928.	1.2	381
9	Deregulation of microRNA-503 Contributes to Diabetes Mellitusâ€“Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia. Circulation, 2011, 123, 282-291.	1.6	374
10	Reciprocal Regulation of MicroRNA-1 and Insulin-Like Growth Factor-1 Signal Transduction Cascade in Cardiac and Skeletal Muscle in Physiological and Pathological Conditions. Circulation, 2009, 120, 2377-2385.	1.6	356
11	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	2.9	350
12	MicroRNA-133a Protects Against Myocardial Fibrosis and Modulates Electrical Repolarization Without Affecting Hypertrophy in Pressure-Overloaded Adult Hearts. Circulation Research, 2010, 106, 166-175.	2.0	347
13	microRNAs in Cardiovascular Diseases. Journal of the American College of Cardiology, 2014, 63, 2177-2187.	1.2	340
14	Long Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology. Circulation Research, 2015, 116, 751-762.	2.0	334
15	Human p300 Protein Is a Coactivator for the Transcription Factor MyoD. Journal of Biological Chemistry, 1996, 271, 9009-9013.	1.6	294
16	MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. Journal of Clinical Investigation, 2010, 120, 2805-2816.	3.9	291
17	MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biology, 2010, 12, 1220-1227.	4.6	289
18	MicroRNAs and cardiac pathology. Nature Reviews Cardiology, 2009, 6, 418-429.	6.1	282

#	Article	IF	Citations
19	Association of theFOXO3ALocus with Extreme Longevity in a Southern Italian Centenarian Study. Rejuvenation Research, 2009, 12, 95-104.	0.9	282
20	MicroRNA-133 Controls Vascular Smooth Muscle Cell Phenotypic Switch In Vitro and Vascular Remodeling In Vivo. Circulation Research, 2011, 109, 880-893.	2.0	280
21	Emerging Role of MicroRNAs in Cardiovascular Biology. Circulation Research, 2007, 101, 1225-1236.	2.0	272
22	Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 63, 920-927.	1.2	270
23	Increased Cardiomyocyte Apoptosis and Changes in Proapoptotic and Antiapoptotic Genes bax and bcl -2 During Left Ventricular Adaptations to Chronic Pressure Overload in the Rat. Circulation, 1999, 99, 3071-3078.	1.6	267
24	Rheb is a Critical Regulator of Autophagy During Myocardial Ischemia. Circulation, 2012, 125, 1134-1146.	1.6	257
25	The Akt-Glycogen Synthase Kinase 3Î² Pathway Regulates Transcription of Atrial Natriuretic Factor Induced by Î²-Adrenergic Receptor Stimulation in Cardiac Myocytes. Journal of Biological Chemistry, 2000, 275, 14466-14475.	1.6	234
26	Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Medicine, 1995, 1, 541-545.	15.2	222
27	Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overloadâ€“Driven Heart Failure Reveals Extent of Immune Activation. Circulation, 2019, 140, 2089-2107.	1.6	212
28	Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20164-20169.	3.3	210
29	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2013, 98, 7-27.	1.8	209
30	Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. Journal of Cellular Physiology, 2008, 214, 316-321.	2.0	204
31	Calcineurin-Mediated Hypertrophy Protects Cardiomyocytes From Apoptosis In Vitro and In Vivo. Circulation Research, 2000, 86, 255-263.	2.0	203
32	MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. Journal of Cell Biology, 2010, 189, 13-22.	2.3	197
33	IÎºB kinase Îµ and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6474-6479.	3.3	195
34	Activation of cAMPâ€“PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nature Medicine, 1997, 3, 775-779.	15.2	187
35	TGFÎ² Triggers miR-143/145 Transfer From Smooth Muscle Cells to Endothelial Cells, Thereby Modulating Vessel Stabilization. Circulation Research, 2015, 116, 1753-1764.	2.0	176
36	Interval Training Normalizes Cardiomyocyte Function, Diastolic Ca ²⁺ Control, and SR Ca ²⁺ Release Synchronicity in a Mouse Model of Diabetic Cardiomyopathy. Circulation Research, 2009, 105, 527-536.	2.0	173

#	Article	IF	Citations
37	MiRâ€133a regulates collagen 1A1: Potential role of miRâ€133a in myocardial fibrosis in angiotensin Iiâ€dependent hypertension. Journal of Cellular Physiology, 2012, 227, 850-856.	2.0	170
38	CaMK4 Gene Deletion Induces Hypertension. Journal of the American Heart Association, 2012, 1, e001081.	1.6	168
39	microRNAs in heart disease: putative novel therapeutic targets?. European Heart Journal, 2010, 31, 649-658.	1.0	148
40	Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovascular Research, 2008, 80, 416-424.	1.8	147
41	ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovascular Research, 2014, 104, 399-411.	1.8	143
42	Circ_Lrp6, a Circular RNA Enriched in Vascular Smooth Muscle Cells, Acts as a Sponge Regulating miRNA-145 Function. Circulation Research, 2019, 124, 498-510.	2.0	140
43	T cell costimulation blockade blunts pressure overload-induced heart failure. Nature Communications, 2017, 8, 14680.	5.8	139
44	Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. American Journal of Cardiology, 1994, 74, 468-473.	0.7	132
45	Inhalation of peptide-loaded nanoparticles improves heart failure. Science Translational Medicine, 2018, 10, .	5.8	132
46	Circulating MicroRNAs and Aerobic Fitness â€“ The HUNT-Study. PLoS ONE, 2013, 8, e57496.	1.1	128
47	DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy. Nature Communications, 2016, 7, 12418.	5.8	127
48	Akt Mediates the Cross-Talk Between Î²-Adrenergic and Insulin Receptors in Neonatal Cardiomyocytes. Circulation Research, 2005, 96, 180-188.	2.0	124
49	Transplantation of low dose CD34 + Kdr + cells promotes vascular and muscular regeneration in ischemic limbs. FASEB Journal, 2004, 18, 1737-1739.	0.2	120
50	Atrial fibrillation and microRNAs. Frontiers in Physiology, 2014, 5, 15.	1.3	119
51	Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nature Reviews Cardiology, 2015, 12, 488-497.	6.1	117
52	MicroRNA-133 Modulates the Î² ₁ -Adrenergic Receptor Transduction Cascade. Circulation Research, 2014, 115, 273-283.	2.0	115
53	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	1.8	114
54	Regulation of Cell Size and Contractile Function by AKT in Cardiomyocytes. Annals of the New York Academy of Sciences, 2004, 1015, 250-260.	1.8	113

#	Article	IF	Citations
55	mTOR regulates brain morphogenesis by mediating GSK3 signaling. Development (Cambridge), 2014, 141, 4076-4086.	1.2	109
56	Heart infarct in NODâ€SCID mice: Therapeutic vasculogenesis by transplantation of human CD34 + cells and low dose CD34 + KDR + cells. FASEB Journal, 2004, 18, 1392-1394.	0.2	107
57	Aerobic interval training enhances cardiomyocyte contractility and Ca2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. Journal of Molecular and Cellular Cardiology, 2007, 43, 354-361.	0.9	106
58	Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet, The, 2020, 395, 1487-1495.	6.3	104
59	Mechanism of Enhanced Cardiac Function in Mice with Hypertrophy Induced by Overexpressed Akt. Journal of Biological Chemistry, 2003, 278, 47622-47628.	1.6	102
60	Akt regulates L-type Ca2+ channel activity by modulating CavÎ±1 protein stability. Journal of Cell Biology, 2009, 184, 923-933.	2.3	101
61	Long Noncoding RNA: a New Player of Heart Failure?. Journal of Cardiovascular Translational Research, 2013, 6, 876-883.	1.1	101
62	MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. Journal of Translational Medicine, 2011, 9, 159.	1.8	95
63	AKT Participates in Endothelial Dysfunction in Hypertension. Circulation, 2004, 109, 2587-2593.	1.6	89
64	miR-128-3p Is a Novel Regulator of Vascular Smooth Muscle Cell Phenotypic Switch and Vascular Diseases. Circulation Research, 2020, 126, e120-e135.	2.0	88
65	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice. Thrombosis and Haemostasis, 2014, 112, 796-802.	1.8	87
66	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. Molecular and Cellular Biology, 2001, 21, 2485-2495.	1.1	86
67	Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. European Journal of Human Genetics, 2013, 21, 1105-1111.	1.4	86
68	Physiological myocardial hypertrophy: how and why?. Frontiers in Bioscience - Landmark, 2008, 13, 312.	3.0	86
69	MicroRNAs in Cardiovascular Biology and Heart Disease. Circulation: Cardiovascular Genetics, 2009, 2, 402-408.	5.1	85
70	The B Subunit of the CAAT-binding Factor NFY Binds the Central Segment of the Co-activator p300. Journal of Biological Chemistry, 1999, 274, 7623-7626.	1.6	80
71	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB Journal, 2010, 24, 1981-1988.	0.2	80
72	The K219T-Lamin mutation induces conduction defects through epigenetic inhibition of SCN5A in human cardiac laminopathy. Nature Communications, 2019, 10, 2267.	5.8	79

#	Article	IF	Citations
73	Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy. Circulation, 2017, 136, 1233-1246.	1.6	78
74	Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1689-1694.	3.3	77
75	SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. Cell Death and Disease, 2021, 12, 50.	2.7	77
76	Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. American Heart Journal, 2006, 151, 674-680.	1.2	76
77	MicroRNA and cardiac pathologies. Physiological Genomics, 2008, 34, 239-242.	1.0	76
78	Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. American Journal of Cardiology, 1988, 62, 745-750.	0.7	74
79	TNFâ€± signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNFâ€± receptor. FASEB Journal, 2002, 16, 1732-1737.	0.2	73
80	Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovascular Research, 2014, 101, 587-596.	1.8	73
81	Association Study on Long-Living Individuals from Southern Italy Identifies rs10491334 in the CAMKIV Gene That Regulates Survival Proteins. Rejuvenation Research, 2011, 14, 283-291.	0.9	72
82	UHRF1 epigenetically orchestrates smooth muscle cell plasticity in arterial disease. Journal of Clinical Investigation, 2018, 128, 2473-2486.	3.9	68
83	MicroRNA-1 Downregulation Increases Connexin 43 Displacement and Induces Ventricular Tachyarrhythmias in Rodent Hypertrophic Hearts. PLoS ONE, 2013, 8, e70158.	1.1	67
84	Novel therapeutic strategies for cardioprotection. , 2014, 144, 60-70.		64
85	Adenoviral RB2/p130 Gene Transfer Inhibits Smooth Muscle Cell Proliferation and Prevents Restenosis After Angioplasty. Circulation Research, 1999, 85, 1032-1039.	2.0	63
86	Cardiotoxic effects, or lack thereof, of antiâ€ErbB2 immunoagents. FASEB Journal, 2009, 23, 3171-3178.	0.2	63
87	Epigenetics: a new mechanism of regulation of heart failure?. Basic Research in Cardiology, 2013, 108, 361.	2.5	63
88	Akt Increases Sarcoplasmic Reticulum Ca2+ Cycling by Direct Phosphorylation of Phospholamban at Thr17. Journal of Biological Chemistry, 2009, 284, 28180-28187.	1.6	62
89	Evidence for Oxidative Activation of c-Mycâ€“Dependent Nuclear Signaling in Human Coronary Smooth Muscle Cells and in Early Lesions of Watanabe Heritable Hyperlipidemic Rabbits. Circulation, 2000, 102, 2111-2117.	1.6	58
90	Akt/Protein Kinase B and Endothelial Nitric Oxide Synthase Mediate Muscular Neovascularization Induced by Tissue Kallikrein Gene Transfer. Circulation, 2004, 110, 1638-1644.	1.6	57

#	Article	IF	Citations
91	Role of the Epigenome in Heart Failure. Physiological Reviews, 2020, 100, 1753-1777.	13.1	57
92	Myocardial sarcoplasmic reticulum Ca²⁺ATPase function is increased by aerobic interval training. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 145-148.	3.1	56
93	The Circulating Level of FABP3 Is an Indirect Biomarker of MicroRNA-1. Journal of the American College of Cardiology, 2013, 61, 88-95.	1.2	56
94	Induced pluripotent stem cellâ€“derived cardiomyocytes in studies of inherited arrhythmias. Journal of Clinical Investigation, 2013, 123, 84-91.	3.9	56
95	A Pentamer Transcriptional Complex Including tal-1 and Retinoblastoma Protein Downmodulates c-kit Expression in Normal Erythroblasts. Molecular and Cellular Biology, 2000, 20, 5330-5342.	1.1	55
96	Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: Impact of N-acetylcysteine. Kidney International, 2005, 68, 2250-2255.	2.6	54
97	Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidationâ€sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB Journal, 2001, 15, 2162-2170.	0.2	53
98	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. Cell Death and Disease, 2016, 7, e2393-e2393.	2.7	51
99	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1166-1175.	1.1	49
100	MicroRNAs Control Gene Expression. Annals of the New York Academy of Sciences, 2008, 1123, 20-29.	1.8	47
101	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 234.	3.0	46
102	Arterial remodeling and atherosclerosis: miRNAs involvement. Vascular Pharmacology, 2011, 55, 106-110.	1.0	45
103	Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography. Cardiovascular Research, 2020, 116, 2239-2246.	1.8	45
104	p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor. Biochemical Journal, 2003, 369, 477-484.	1.7	44
105	Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT. Journal of Molecular and Cellular Cardiology, 2004, 37, 905-912.	0.9	44
106	Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12033-12038.	3.3	44
107	microRNAs in hypertrophy and heart failure. Experimental Biology and Medicine, 2011, 236, 125-131.	1.1	43
108	Peptidomimetic Targeting of Ca _v Î²2 Overcomes Dysregulation of the L-Type Calcium Channel Density and Recovers Cardiac Function. Circulation, 2016, 134, 534-546.	1.6	42

#	Article	IF	Citations
109	MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2345-2357.	1.1	42
110	Cardiac-specific overexpression of E40K active Akt prevents pressure overload-induced heart failure in mice by increasing angiogenesis and reducing apoptosis. Cell Death and Differentiation, 2007, 14, 1060-1062.	5.0	40
111	Circulating MicroRNAs As Potential Biomarkers of Coronary Artery Disease. Circulation Research, 2010, 107, 573-574.	2.0	40
112	SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovascular Research, 2012, 96, 381-390.	1.8	40
113	Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications. Current Cardiology Reviews, 2011, 7, 201-212.	0.6	40
114	The Might of MicroRNA in Mitochondria. Circulation Research, 2012, 110, 1540-1542.	2.0	37
115	miR-21 and cardiac fibrosis: another brick in the wall?: Figure 1. European Heart Journal, 2015, 36, 2139-2141.	1.0	34
116	miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFÎ² signaling. Nature Communications, 2018, 9, 2418.	5.8	34
117	Effects of Akt on Cardiac Myocytes. Circulation Research, 2006, 99, 339-341.	2.0	33
118	c-Myc Oncoprotein: Cell Cycle-Related Events and New Therapeutic Challenges in Cancer and Cardiovascular Diseases. Cell Cycle, 2003, 2, 324-327.	1.3	32
119	Fatty acid percentage in erythrocyte membranes of atrial flutter/fibrillation patients and controls. Journal of Interventional Cardiac Electrophysiology, 2010, 27, 95-99.	0.6	32
120	RNA (Epi)genetics in cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2015, 89, 11-16.	0.9	32
121	Human cardiomyocyte calcium handling and transverse tubules in midâ€stage of postâ€myocardialâ€infarction heart failure. ESC Heart Failure, 2018, 5, 332-342.	1.4	32
122	Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release. European Heart Journal, 2021, 42, 2780-2792.	1.0	32
123	TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. Journal of Hypertension, 2015, 33, 1301-1309.	0.3	29
124	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
125	Myocardial Fibrosis Induced by Exposure to Subclinical Lipopolysaccharide Is Associated with Decreased miR-29c and Enhanced NOX2 Expression in Mice. PLoS ONE, 2014, 9, e107556.	1.1	28
126	Myeloid-Derived Growth Factor Protects Against Pressure Overloadâ€“Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca ²⁺ -ATPase Expression in Cardiomyocytes. Circulation, 2021, 144, 1227-1240.	1.6	27

#	Article	IF	Citations
127	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
128	Heart failure: Targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. International Journal of Biochemistry and Cell Biology, 2008, 40, 1643-1648.	1.2	26
129	Generation of Site-Directed Mutagenesis by Extralong, High-Fidelity Polymerase Chain Reaction. Analytical Biochemistry, 1996, 233, 142-144.	1.1	24
130	Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Medical Genetics, 2013, 14, 11.	2.1	24
131	Electroactive polyurethane/siloxane derived from castor oil as a versatile cardiac patch, part I: Synthesis, characterization, and myoblast proliferation and differentiation. Journal of Biomedical Materials Research - Part A, 2016, 104, 775-787.	2.1	24
132	The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cellâ€“monocyte crosstalk and protects against atherosclerosis via the NF-ÎºB pathway. European Heart Journal, 2022, 43, 4562-4576.	1.0	24
133	Carbon Monoxide Levels Experienced by Heavy Smokers Impair Aerobic Capacity and Cardiac Contractility and Induce Pathological Hypertrophy. Inhalation Toxicology, 2008, 20, 635-646.	0.8	23
134	Scavenger receptors and non-coding RNAs: relevance in atherogenesis. Cardiovascular Research, 2016, 109, 24-33.	1.8	23
135	Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. European Heart Journal, 2013, 34, 3400-3402.	1.0	22
136	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
137	The long noncoding RNA landscape in cardiovascular disease. Current Opinion in Cardiology, 2018, 33, 282-289.	0.8	21
138	Synergistic role of E1A-Binding proteins and tissue-specific transcription factors in differentiation. , 1997, 67, 423-431.		20
139	Electroactive polyurethane/siloxane derived from castor oil as a versatile cardiac patch, part II: HLâ€1 cytocompatibility and electrical characterizations. Journal of Biomedical Materials Research - Part A, 2016, 104, 1398-1407.	2.1	20
140	Epigenetics in heart failure. Annals of the New York Academy of Sciences, 2010, 1188, 159-164.	1.8	19
141	The involvement of epigenetics in vascular disease development. International Journal of Biochemistry and Cell Biology, 2019, 107, 27-31.	1.2	19
142	T Cell Costimulation Blockade Blunts Age-Related Heart Failure. Circulation Research, 2020, 127, 1115-1117.	2.0	19
143	Characterization of caveolae from rat heart: Localization of postreceptor signal transduction molecules and their rearrangement after norepinephrine stimulation. , 2000, 77, 529-539.		18
144	RNA Silencing: Small RNAâ€Mediated Posttranscriptional Regulation of mRNA and the Implications for Heart Electropathophysiology. Journal of Cardiovascular Electrophysiology, 2009, 20, 230-237.	0.8	18

#	Article	IF	Citations
145	Therapeutic applications of noncoding RNAs. Current Opinion in Cardiology, 2015, 30, 213-221.	0.8	18
146	Expansion of specific Î±Î²+ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with Coxsackievirus B infection. Human Immunology, 2003, 64, 194-210.	1.2	17
147	Relation of Various Plasma Growth Factor Levels in Patients With Stable Angina Pectoris and Total Occlusion of a Coronary Artery to the Degree of Coronary Collaterals. American Journal of Cardiology, 2006, 97, 472-476.	0.7	17
148	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
149	Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatology International, 2019, 39, 239-243.	1.5	17
150	Unilineage hematopoietic differentiation in bulk and single cell culture. Stem Cells, 2009, 16, 51-73.	1.4	16
151	Dissecting the transcriptome in cardiovascular disease. Cardiovascular Research, 2022, 118, 1004-1019.	1.8	16
152	Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. Journal of Cellular Biochemistry, 1997, 64, 579-585.	1.2	15
153	MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis. Cardiovascular Research, 2008, 79, 551-552.	1.8	15
154	Reliable resequencing of the human dystrophin locus by universal long polymerase chain reaction and massive pyrosequencing. Analytical Biochemistry, 2010, 406, 176-184.	1.1	15
155	Unexpectedly low mutation rates in betaâ€myosin heavy chain and cardiac myosin binding protein genes in italian patients with hypertrophic cardiomyopathy. Journal of Cellular Physiology, 2011, 226, 2894-2900.	2.0	15
156	Exercise training reverses myocardial dysfunction induced by CaMKIIÎ´_Coverexpression by restoring Ca²⁺homeostasis. Journal of Applied Physiology, 2016, 121, 212-220.	1.2	14
157	Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis. Journal of the American College of Cardiology, 2016, 67, 2029-2031.	1.2	13
158	Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells. Journal of Visualized Experiments, 2013, , .	0.2	12
159	The RNA Methylome Blackboard. Circulation, 2019, 139, 546-548.	1.6	12
160	Reduced aerobic capacity causes leaky ryanodine receptors that trigger arrhythmia in a rat strain artificially selected and bred for low aerobic running capacity. Acta Physiologica, 2014, 210, 854-864.	1.8	11
161	Divergent Transcription of the Nkx2-5 Locus Generates Two Enhancer RNAs with Opposing Functions. IScience, 2020, 23, 101539.	1.9	11
162	Long non-coding RNA H19: a new avenue for RNA therapeutics in cardiac hypertrophy?. European Heart Journal, 2020, 41, 3475-3476.	1.0	11

#	Article	IF	Citations
163	rs41291957 controls miRâ€143 and miRâ€145 expression and impacts coronary artery disease risk. EMBO Molecular Medicine, 2021, 13, e14060.	3.3	11
164	Endoplasmic reticulum stress at the crossroads of progeria and atherosclerosis. EMBO Molecular Medicine, 2019, 11, .	3.3	10
165	Interleukin-6 trans-signalling and risk of future cardiovascular events: a new avenue for atheroprotection?. Cardiovascular Research, 2019, 115, 8-9.	1.8	10
166	Role of microRNAs in haemopoiesis, heart hypertrophy and cancer. Biochemical Society Transactions, 2008, 36, 1206-1210.	1.6	9
167	An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes. Cardiovascular Research, 2018, 114, 409-416.	1.8	9
168	Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination. Thrombosis and Haemostasis, 2022, 122, 1706-1711.	1.8	9
169	Nano-miR-133a Replacement Therapy Blunts Pressure Overloadâ€"Induced Heart Failure. Circulation, 2021, 144, 1973-1976.	1.6	9
170	Role of Reticulated Platelets in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 527-539.	1.1	9
171	Stem Cells for Cardiomyocyte Regeneration: State of the Art. Annals of the New York Academy of Sciences, 2005, 1047, 376-385.	1.8	8
172	Endothelial-to-Mesenchymal Transition and MicroRNA-21. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 165-166.	1.1	8
173	Genetic Variants in CCNB1 Associated With Differential Gene Transcription and Risk of Coronary In-Stent Restenosis. Circulation: Cardiovascular Genetics, 2014, 7, 59-70.	5.1	8
174	MicroRNAs and pulmonary hypertension: a tight link. Cardiovascular Research, 2016, 111, 163-164.	1.8	8
175	Human embryonic stem cell-derived cardiomyocytes: inducing strategies. Regenerative Medicine, 2006, 1, 183-194.	0.8	7
176	Sources of Cardiomyocytes for Stem Cell Therapy: An Update. Pediatric Research, 2006, 59, 79R-83R.	1.1	7
177	microRNAâ€132: a new biomarker of heart failure at last?. European Journal of Heart Failure, 2018, 20, 86-88.	2.9	7
178	MicroRNAs as Companion Biomarkers for the Diagnosis and Prognosis of Acute Coronary Syndromes. Circulation Research, 2019, 125, 341-342.	2.0	7
179	Synthetic recovery of impulse propagation in myocardial infarction via silicon carbide semiconductive nanowires. Nature Communications, 2022, 13, 6.	5.8	7
180	Oneâ€Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimusâ€Eluting Stents in High Bleeding Risk Patients. Journal of the American Heart Association, 2022, 11, e023454.	1.6	7

#	Article	IF	Citations
181	Left atrial appendage closure with the II generation Ultraseal device:ÂAn international registry. The LIGATE study. Catheterization and Cardiovascular Interventions, 2022, 100, 620-627.	0.7	7
182	HEXIM1: a new player in myocardial hypertrophy?. Cardiovascular Research, 2013, 99, 1-3.	1.8	6
183	A G613A missense in the Hutchinsonâ€™s progeria lamin A/C gene causes a lone, autosomal dominant atrioventricular block. Immunity and Ageing, 2014, 11, 19.	1.8	6
184	Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	6
185	Circular RNAs and heart failure: new players for an old disease. Cardiovascular Research, 2017, 113, 254-255.	1.8	6
186	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Andersonâ€“Fabry disease. Cell Death and Disease, 2021, 12, 1150.	2.7	6
187	Antiphosphotyrosine Immunoprecipitation of an Insulin-Stimulated Receptor Phosphatase Activity from FRTL5 Cells*. Endocrinology, 1991, 128, 2949-2957.	1.4	5
188	ATP6V0A1 Polymorphism and MicroRNA-637. Circulation: Cardiovascular Genetics, 2011, 4, 337-338.	5.1	5
189	Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. Clinical Reviews in Allergy and Immunology, 2018, 55, 254-270.	2.9	5
190	MicroRNA signatures predict early major coronary events in middle-aged men and women. Cell Death and Disease, 2020, 11, 74.	2.7	5
191	FABP3 as Biomarker of Heart Pathology. Biomarkers in Disease, 2015, , 439-454.	0.0	5
192	Effects of Angiotensin Converting Enzyme Inhibitors on Left Ventricular Hypertrophy. Drugs, 1993, 46, 88-94.	4.9	4
193	Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis. European Cardiology Review, 2021, 16, e39.	0.7	4
194	Phosphorylation of regulatory proteins CaMK, PLN and AKT precedes cardiomyocyte adaptation to exercise training. Journal of Molecular and Cellular Cardiology, 2006, 40, 1006.	0.9	3
195	On the road to the definition of the cardiac miRNome in human disease states. Journal of Molecular and Cellular Cardiology, 2008, 45, 162-164.	0.9	3
196	Reply. Journal of the American College of Cardiology, 2014, 64, 2181-2182.	1.2	3
197	Exome sequencing of a family with lone, autosomal dominant atrial flutter identifies a rare variation in ABCB4 significantly enriched in cases. BMC Genetics, 2015, 16, 15.	2.7	3
198	Endovascular treatment vs. intravenous thrombolysis alone for ischaemic stroke: a meta-analysis of randomised controlled trials. EuroIntervention, 2016, 12, e271-e281.	1.4	3

#	Article	IF	Citations
199	Mass cytometry of platelet-rich plasma: a new approach to analyze platelet surface expression and reactivity. Platelets, 2022, 33, 841-848.	1.1	3
200	Deciphering the Î²â€adrenergic response in human embryonic stem cellâ€derivedâ€cardiac myocytes: closer to clinical use?. British Journal of Pharmacology, 2008, 153, 625-626.	2.7	2
201	Immersion before dry simulated dive reduces cardiomyocyte function and increases mortality after decompression. Journal of Applied Physiology, 2010, 109, 752-757.	1.2	2
202	MicroRNA-Dependent Control of the Cardiac Fibroblast Secretome. Circulation Research, 2013, 113, 1099-1101.	2.0	2
203	Bowel preparation for colonoscopy and hypokalemia: at the heart of the problem!. Gastrointestinal Endoscopy, 2017, 86, 680-683.	0.5	2
204	RNA binding protein and microRNA control of endothelial cell function. Cardiovascular Research, 2019, 115, 1690-1691.	1.8	2
205	Mitral Valve Stenosis after Transcatheter Aortic Valve Replacement: Case Report and Review of the Literature. Cardiovascular Revascularization Medicine, 2019, 20, 1196-1202.	0.3	2
206	Impact of myocardial injury on mortality in patients with COVID-19: a meta-analysis. Hellenic Journal of Cardiology, 2020, 62, 253-255.	0.4	2
207	MicroRNA-132 Inhibition Prevents Myocardial Hypertrophy and HeartÂFailure in Pigs. Journal of the American College of Cardiology, 2021, 77, 2936-2938.	1.2	2
208	MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. Journal of Clinical Investigation, 2010, 120, 3735-3735.	3.9	2
209	MicroRNA and Cardiovascular Disorders with a Focus on Angiogenesis. , 2013, , 479-497.		1
210	Reply. JACC: Cardiovascular Interventions, 2014, 7, 448-449.	1.1	1
211	Chemerin processing in the myocardium: A mechanism in search of a function. Journal of Molecular and Cellular Cardiology, 2016, 100, 21-24.	0.9	1
212	Akt regulates L-type Ca2+channel activity by modulating CavÎ±1 protein stability. Journal of General Physiology, 2009, 133, i4-i4.	0.9	1
213	196â€ƒCardiovascular magnetic resonance characterization of myocardial injury in recovered COVID-19 patients with elevated troponins during hospital stay. European Heart Journal Supplements, 2021, 23, .	0.0	1
214	State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy. Heart Failure Monitor, 2008, 5, 112-8.	0.7	1
215	241â€ƒTranscatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.0	1
216	Cardiopulmonary receptors and coronary circulation. Journal of the Autonomic Nervous System, 1990, 30, S173-S177.	1.9	0

#	Article	IF	Citations
217	Epigenetics in Cardiovascular Biology. , 2012, , 331-340.		0
218	A collagen membrane-based engineered heart tissue improves cardiac function in ischemic rat hearts. Bioinspired, Biomimetic and Nanobiomaterials, 2013, 2, 20-27.	0.7	0
219	Dr. John Ross Jr.. European Heart Journal, 2019, 40, 2004-2005.	1.0	0
220	Scientists on the Spot: non-coding RNAs and heart failure. Cardiovascular Research, 2019, 115, e164-e165.	1.8	0
221	Defining circulating mononuclear cells in heart failure through single-cell RNA sequencing: new insights for an old disease. Cardiovascular Research, 2021, 117, 341-342.	1.8	0
222	Mind your heart: the epigenetic consequences of heart failure on brain function. EMBO Molecular Medicine, 2021, 13, e13785.	3.3	0
223	Engineered Membranes Improve Cardiac Function in Ischemic Rat Hearts. , 2010, , .		0
224	FABP3 as Biomarker of Heart Pathology. , 2014, , 1-13.		0
225	401 Myocardial viability and ischaemia assessment in chronic coronary total occlusions according to collaterals distribution: a retrospective analysis. European Heart Journal Supplements, 2021, 23, .	0.0	0
226	349â€ƒLeft atrial appendage closure with the II generation ultraseal device: an international registry. The ligate study. European Heart Journal Supplements, 2021, 23, .	0.0	0
227	548 Colchicine in patients with coronary artery disease: a meta-analysis of randomized trials. European Heart Journal Supplements, 2021, 23, .	0.0	0
228	456â€ƒMonotherapy with a P2Y12 inhibitor or aspirin for patients with established atherosclerosis: an updated meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.0	0
229	750â€ƒMitral annulus disjunction in consecutive patients undergoing cardiovascular magnetic resonance: arrhythmogenic substrate or anatomical variant?. European Heart Journal Supplements, 2021, 23, .	0.0	0
230	112â€ƒSafety and biochemical efficacy of sodiumâ€“glucose cotransporter 2 inhibitors based on cardiovascular risk profile and volume status in a real-world diabetic population. European Heart Journal Supplements, 2021, 23, .	0.0	0
231	480â€ƒCatheter pulmonary vein ablation vs. medical therapy or atrioventricular node ablation and resynchronization in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.0	0
232	21â€ƒDirect oral anticoagulants vs. vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.0	0